Gastrointestinal Therapeutics

Gastrointestinal Therapeutics

Global Gastrointestinal Therapeutics Market to Reach $99.2 Billion by 2030
The global market for Gastrointestinal Therapeutics estimated at US$69.9 Billion in the year 2023, is expected to reach US$99.2 Billion by 2030, growing at a CAGR of 4.5% over the period 2023-2030. Crohn`s Disease End-Use, one of the segments analyzed in the report, is expected to record 4.3% CAGR and reach US$19 Billion by the end of the analysis period. Growth in the Ulcerative Colitis End-Use segment is estimated at 4.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $18.4 Billion, While China is Forecast to Grow at 6.9% CAGR
The Gastrointestinal Therapeutics market in the U.S. is estimated at US$18.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$22.2 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

What to Expect the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 44 Featured) -
  • AbbVie, Inc.
  • Alfa Wassermann, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • Ardelyx, Inc.
  • Astellas Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Celgene Corporation
  • Cosmo Pharmaceuticals NV
  • Drais Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Enlivex Therapeutics ltd.
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals, Inc.
  • FF Pharma
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Inc.
  • Hutchison MediPharma Limited
  • Immune Pharmaceuticals, Inc.
  • InDex Pharmaceuticals Holding AB
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lexicon Pharmaceuticals, Inc.
  • Lipid Therapeutics GmbH
  • Meda AB
  • Merck & Co., Inc.
  • Mesoblast Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Mochida Pharmaceutical Co., Ltd.
  • Morphotek, Inc.
  • Neovacs S.A.
  • Nestle SA
  • Norgine BV
  • Novartis AG
  • Pfizer, Inc.
  • Procter & Gamble Company, The
  • Qu Biologics Inc.
  • RedHill Biopharma Ltd.
  • Sterna Biologicals GmbH & Co. KG
  • Synthetic Biologics, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • TiGenix NV
  • Tillotts Pharma AG
  • TopiVert Ltd.
  • UCB SA
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Gastrointestinal Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Gastrointestinal Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for GERD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for GERD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for GERD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Gastrointestinal Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 14: World Recent Past, Current & Future Analysis for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Crohn`s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
TABLE 20: Canada Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Canada Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Canada 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 23: Japan Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Japan Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Japan 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 26: China Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: China Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: China 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 29: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Gastrointestinal Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 32: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 35: France Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: France Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: France 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 38: Germany Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Germany Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Germany 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
TABLE 41: Italy Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Italy Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Italy 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 44: UK Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: UK Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: UK 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
SPAIN
TABLE 47: Spain Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Spain Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Spain 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
RUSSIA
TABLE 50: Russia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Russia Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Russia 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Rest of Europe Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Rest of Europe 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
AUSTRALIA
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 62: Australia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Australia Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Australia 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
INDIA
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 65: India Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: India Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: India 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 68: South Korea Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: South Korea Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: South Korea 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Rest of Asia-Pacific Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
LATIN AMERICA
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 74: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Gastrointestinal Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 77: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 80: Argentina Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Argentina Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Argentina 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
BRAZIL
TABLE 83: Brazil Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Brazil Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Brazil 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
MEXICO
TABLE 86: Mexico Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Mexico Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Mexico 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Latin America Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Latin America 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
MIDDLE EAST
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 92: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Gastrointestinal Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 95: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
IRAN
TABLE 98: Iran Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Iran Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Iran 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
ISRAEL
TABLE 101: Israel Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Israel Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Israel 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Saudi Arabia Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Saudi Arabia 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 107: UAE Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: UAE Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: UAE 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Rest of Middle East Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Rest of Middle East 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
AFRICA
Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 113: Africa Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Africa Historic Review for Gastrointestinal Therapeutics by End-Use - Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Africa 16-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Crohn`s Disease, Ulcerative Colitis, GERD and Other End-Uses for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings